Results from the phase 3 gene therapy trial for painful diabetic peripheral neuropathy (DPN) have been published online by Clinical and Translational Science and suggest excellent safety profile and promising efficacy.
KEY POINTS
VM202 (donaperminogene seltoplasmid) is a first-in-class, proprietary, non-viral, potentially regenerative plasmid DNA gene therapy.